Flagship biotech 'Rings' in $85M+ for next-gen gene therapy effort
Another Flagship Pioneering creation is spotlighting a funding round this week, as Ring Therapeutics brought in an $86.5 million Series C, part of a strong March for private biotechs despite worries about a financing slowdown for drug R&D.
Some next-generation gene therapy makers think it’s time to pass the baton from one-and-done treatments that use adenovirus associated (AAV) vectors to new delivery methods. Ring believes that its anellovirus-based candidates can be dosed more than once.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
